Gosuranemab

Unassigned

New Medicines

Progressive supranuclear palsy

Information

New molecular entity
Biogen
Biogen

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Dec 19The primary endpoint of the PII PASSPORT study was not met, and further development of gosuranemab in progressive supranuclear palsy (PSP) will not be pursued [6].

Category

Humanised monoclonal antibody directed against extracellular, N-terminally fragmented forms of tau, known as eTau, which arise in patients with PSP due to a genetic defect.
In 2015, progressive supranuclear palsy affected approximately 1.4 in 10,000 people in the European Union (EU) [1].
Progressive supranuclear palsy
Intravenous infusion

Further information

Yes
To be confirmed

Evidence based evaluations